COMP <GO>
UHS vs ABBV // EV/EBITDA & P/E VALUATION
Universal Health Services Inc. (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: UHS 6
— ABBV 7
▲ EV/EBITDA & P/E VALUATION LEADER: UHS
LAST: $176.61 (+2.57%) • MKT CAP: $10.41B
valuation
5.0x
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
valuation
33.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (UHS VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | UHS | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 70.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 14.10% | 29.00% | -14.90 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 5.0x | 33.3x | -28.30 | UHS | /valuation <GO> |
| Free Cash Flow Yield | 8.16% | 3.47% | +4.69 | UHS | /fcf-yield <GO> |
| Operating Margin | 11.50% | 24.60% | -13.10 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 8.60% | 6.90% | +1.70 | UHS | /net-margins <GO> |
| Revenue Growth (YoY) | 9.70% | 8.60% | +1.10 | UHS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.49% | 2.27% | -1.78 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.11 | 5.33 | -2.22 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | UHS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.5 | 65.1 | -18.60 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.04 | 1.15 | -0.11 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 6.5x | 113.1x | -106.60 | UHS | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.41B | $513.86B | -$503.45B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | UHS REV | ABBV REV | UHS GROSS % | ABBV GROSS % | UHS FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $17.36B | $61.16B | — | 70.2% | $849.2M | $17.82B |
| FY 2024 | $15.83B | $56.33B | — | 70.0% | $1.12B | $17.83B |
| FY 2023 | $14.28B | $54.32B | — | — | $625.1M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
UHS // BETA 1.04
ABBV // BETA 1.15